93 related articles for article (PubMed ID: 28650526)
21. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Schultze-Mosgau MH; Höchel J; Prien O; Zimmermann T; Brooks A; Bush J; Rottmann A
Clin Pharmacokinet; 2018 Aug; 57(8):1001-1015. PubMed ID: 29330782
[TBL] [Abstract][Full Text] [Related]
23. A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a
Singh RSP; Dowty ME; Salganik M; Brodfuehrer JI; Walker GS; Sharma R; Beebe JS; Danto SI
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):815-825. PubMed ID: 35506501
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
25. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS
Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
[TBL] [Abstract][Full Text] [Related]
28. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
30. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
[TBL] [Abstract][Full Text] [Related]
31. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
[TBL] [Abstract][Full Text] [Related]
32. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
[TBL] [Abstract][Full Text] [Related]
34. The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [
Burkard U; Desch M; Shatillo Y; Wunderlich G; Mack SR; Schlecker C; Teitelbaum AM; Liu P; Chan TS
Clin Drug Investig; 2022 Jan; 42(1):87-99. PubMed ID: 34936055
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
36. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
Sun H; Ting L; Machineni S; Praestgaard J; Kuemmell A; Stein DS; Sunkara G; Kovacs SJ; Villano S; Tanaka SK
Antimicrob Agents Chemother; 2016 Dec; 60(12):7431-7435. PubMed ID: 27736760
[TBL] [Abstract][Full Text] [Related]
37. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.
Castelli MC; Wong DF; Friedman K; Riley MG
Clin Ther; 2011 Jul; 33(7):934-45. PubMed ID: 21722960
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
